MA52737A - Vecteurs de virus adéno-associés pour le traitement de mucopolysaccharidoses de type iv a - Google Patents

Vecteurs de virus adéno-associés pour le traitement de mucopolysaccharidoses de type iv a

Info

Publication number
MA52737A
MA52737A MA052737A MA52737A MA52737A MA 52737 A MA52737 A MA 52737A MA 052737 A MA052737 A MA 052737A MA 52737 A MA52737 A MA 52737A MA 52737 A MA52737 A MA 52737A
Authority
MA
Morocco
Prior art keywords
adeno
treatment
associated virus
virus vectors
mucopolysaccharidoses type
Prior art date
Application number
MA052737A
Other languages
English (en)
Inventor
Tubert María Fátima Bosch
Virginia Areba Haurigot
Sanchez Albert Ribera
Clares Víctor Sanchez
Original Assignee
Esteve Pharmaceuticals Sa
UNIV AUTòNOMA DE BARCELONA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa, UNIV AUTòNOMA DE BARCELONA filed Critical Esteve Pharmaceuticals Sa
Publication of MA52737A publication Critical patent/MA52737A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material
    • C12N2750/14152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
MA052737A 2018-05-30 2019-05-27 Vecteurs de virus adéno-associés pour le traitement de mucopolysaccharidoses de type iv a MA52737A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18382373 2018-05-30

Publications (1)

Publication Number Publication Date
MA52737A true MA52737A (fr) 2021-04-14

Family

ID=62530167

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052737A MA52737A (fr) 2018-05-30 2019-05-27 Vecteurs de virus adéno-associés pour le traitement de mucopolysaccharidoses de type iv a

Country Status (20)

Country Link
US (2) US12146169B2 (fr)
EP (1) EP3802803A1 (fr)
JP (1) JP7369403B2 (fr)
KR (1) KR102870949B1 (fr)
CN (1) CN113474453B (fr)
AR (1) AR115449A1 (fr)
AU (1) AU2019275969B2 (fr)
BR (1) BR112020024377A2 (fr)
CA (1) CA3101659A1 (fr)
CO (1) CO2020015942A2 (fr)
IL (1) IL279054B2 (fr)
MA (1) MA52737A (fr)
MX (1) MX2020012911A (fr)
MY (1) MY204731A (fr)
PH (1) PH12020552041A1 (fr)
SG (1) SG11202011777PA (fr)
TW (1) TWI841566B (fr)
UA (1) UA128788C2 (fr)
WO (1) WO2019228950A1 (fr)
ZA (1) ZA202007406B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3829619A4 (fr) * 2018-07-27 2022-05-18 REGENXBIO Inc. Traitement de la mucopolysaccharidose iva
CA3168251A1 (fr) * 2020-01-29 2021-08-05 Regenxbio Inc. Traitement de la mucopolysaccharidose iva
WO2024144003A1 (fr) * 2022-12-29 2024-07-04 주식회사 녹십자 Composition pour le traitement d'un dysmorphisme facial dans la mucopolysaccharidose
WO2025111316A1 (fr) * 2023-11-20 2025-05-30 The Nemours Foundation Thérapie génique lentivirale contre la mucopolysaccharidose iva

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014946A1 (fr) * 2002-08-07 2004-02-19 Neworgen Limited Nouvelle proteine homo avec fonction de suppression du cancer et sa sequence de codage
US7972593B2 (en) * 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2947468C (fr) * 2014-05-14 2022-10-25 Laboratorios Del Dr. Esteve S.A. Vecteurs derives de virus adeno-associes pour le traitement de troubles du stockage lysosomal
US11338046B2 (en) 2016-09-30 2022-05-24 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Also Published As

Publication number Publication date
UA128788C2 (uk) 2024-10-23
US12146169B2 (en) 2024-11-19
MY204731A (en) 2024-09-11
AU2019275969A1 (en) 2020-12-24
IL279054B1 (en) 2025-07-01
IL279054B2 (en) 2025-11-01
KR102870949B1 (ko) 2025-10-14
JP2021526023A (ja) 2021-09-30
AR115449A1 (es) 2021-01-20
JP7369403B2 (ja) 2023-10-26
US20250075194A1 (en) 2025-03-06
CN113474453B (zh) 2024-01-12
WO2019228950A1 (fr) 2019-12-05
BR112020024377A2 (pt) 2021-03-02
CO2020015942A2 (es) 2021-03-08
IL279054A (en) 2021-01-31
US20210214695A1 (en) 2021-07-15
CA3101659A1 (fr) 2019-12-05
PH12020552041A1 (en) 2021-06-28
EP3802803A1 (fr) 2021-04-14
CN113474453A (zh) 2021-10-01
ZA202007406B (en) 2024-08-28
SG11202011777PA (en) 2020-12-30
KR20210027266A (ko) 2021-03-10
AU2019275969B2 (en) 2025-07-10
MX2020012911A (es) 2021-02-26
TWI841566B (zh) 2024-05-11
TW202016315A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3893940A4 (fr) Polythérapie pour le traitement de la dystrophie musculaire
MA47719A (fr) Esketamine pour le traitement de la dépression
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
DK3807413T3 (da) Adenoassocieret virusvektorfremføring af muskelspecifik mikrodystrofin til behandling af muskeldystrofi
MA45052A (fr) Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
EP3474863A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
EP3455205A4 (fr) Peptidomimétiques pour le traitement d'une infection à norovirus
EP3504187A4 (fr) Utilisation de la pridopidine pour le traitement du déclin fonctionnel
MA50409A (fr) Polythérapies pour le traitement du cancer
MA44119A (fr) Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale
EP3389671A4 (fr) Oligomères antisens pour le traitement du syndrome d'alagille
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
MA48637A (fr) Polythérapies pour le traitement du cancer
EP3503890A4 (fr) Utilisation de la pridopidine pour le traitement des dystonies
EP3405183A4 (fr) Dérivés d'adamatane pour le traitement d'une infection à filovirus
EP3403675A4 (fr) Virion viral adéno-associé pour son utilisation dans le traitement de l'épilepsie
EP3344325A4 (fr) Administration locale de médicaments pour le traitement de l'asthme
EP3496662A4 (fr) Protéine dérivée de la soie pour le traitement d'une inflammation
EP3621635A4 (fr) Virus enveloppé résistant à l'inactivation du complément pour le traitement du cancer
EP3500278A4 (fr) Méthodes et compositions pour le traitement d'affections à l'aide d'un virus adéno-associé recombinant auto-complémentaire
MA52737A (fr) Vecteurs de virus adéno-associés pour le traitement de mucopolysaccharidoses de type iv a
EP3766497A4 (fr) Médicament pour le traitement de la toux